Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FaR-RMS treatment protocol for newly diagnosed and relapsed rhabdomyosarcoma
MOH_2020-05-27_008978Phase 3Not yet recruiting
- Sponsor
- ד"ר איריס קוונצל
- Start
- Feb 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, ifosfamide, vincristine, actinomycin D, doxorubicin and 2 more in rhabdomyosarcoma (RMS) (14 arms), sponsored by ד"ר איריס קוונצל. Primary endpoint: Not reported. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
irinotecanifosfamidevincristineactinomycin Ddoxorubicin
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on MOH_2020-05-27_008978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-27_008978.